# LYSA (The Lymphoma Study Association)

Source: https://onco.cc/companies/lysa/  
OnCo record `lysa` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.

## Summary

LYSA was formed in 2012 by merging GELA (founded 1984) and GOELAMS; LYSARC is its academic research organisation. GELA's LNH-98.5 was the trial that added rituximab to CHOP and changed the outcome of DLBCL worldwide, and PRIMA established rituximab maintenance in follicular lymphoma. LYSA co-ran POLARIX (polatuzumab-R-CHP) and leads trials of bispecific antibodies, CAR-T sequencing and PET-guided therapy across France, Belgium and Portugal. It maintains a national lymphoma pathology review network (Lymphopath) and the REALYSA real-world cohort.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: LYSA; GELA; Groupe d'Etude des Lymphomes de l'Adulte; GOELAMS; LYSARC
- Tags: cooperative-group
- HQ: Pierre-Bénite (Lyon)
- Type: cooperative-group
- Website: https://www.lysa-lymphoma.org

## Notes

- LNH-98.5 (R-CHOP)
- PRIMA (rituximab maintenance)
- POLARIX (with Roche)
- REALYSA cohort and Lymphopath

## Sources

- LYSA: https://www.lysa-lymphoma.org

## Connected records

- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Glofitamab](https://onco.cc/drugs/glofitamab/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [FDG PET](https://onco.cc/technologies/fdg-pet/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- companies: [German Lymphoma Alliance](https://onco.cc/companies/german-lymphoma-alliance/), [International Extranodal Lymphoma Study Group](https://onco.cc/companies/ielsg/)
- institutions: [Centre Henri Becquerel](https://onco.cc/institutions/centre-henri-becquerel/), [Institut Curie](https://onco.cc/institutions/institut-curie/)
- trials: [POLARIX](https://onco.cc/trials/polarix/), [PRIMA / ENGOT-OV26](https://onco.cc/trials/prima/)
- people: [Franck Morschhauser](https://onco.cc/people/franck-morschhauser/), [Gilles Salles](https://onco.cc/people/gilles-salles/), [Hervé Tilly](https://onco.cc/people/herve-tilly/), [Steven Le Gouill](https://onco.cc/people/steven-le-gouill/)

---
JSON: https://onco.cc/api/v1/entities/lysa.json